Mary Spellman is an Epidermolysis Bullosa physician affiliated with Phio Pharmaceuticals. OpenAlex indexes 45 publications with 1,685 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Updated 27 Oct 2026
Mary Spellman, M.D., is profiled from the public federal record. The public record shows 45 publications with 1,685 citations (h-index 15), centered on Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Atopic Dermatitis / Eczema. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 1 companies.
- Top research focus: Epidermolysis Bullosa
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dermatologytimes.com ↗
- Chief Medical Officer and Senior Vice President of Research & Development
Castle Creek Pharmaceuticals
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pharmatimes.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
- Chief Medical Officer
Revance Therapeutics (prior role)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Evaluate RLS-1496 Topical Cream for Actinic Keratosis
Sponsor: Rubedo Life Sciences, Inc.
- Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Sponsor: Azitra Inc.
- A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
Sponsor: Castle Creek Pharmaceuticals, LLC
Industry payments
Updated 27 Oct 2026
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BioCryst Pharmaceuticals, Inc.Program year20253 payments
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PD-1–directed intratumoral immunotherapy for cutaneous carcinomas: Interim results from an ongoing study of INTASYL PH-762.
Journal of Clinical Oncology
2025 - 0470 Clinical study of intratumoral PH-762 targeting PD-1 for cutaneous carcinomas
Journal of Investigative Dermatology
2025 - 610 PD-1-directed intratumoral immunotherapy for cutaneous carcinomas: a clinical study of INTASYL PH-762
Regular and Young Investigator Award Abstracts
2025
Background & recognition
Updated 27 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
- Mary C. Spellman
MD (name and credential as listed on the author page)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dermatologytimes.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pharmatimes.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dermatologytimes.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”